Tonix Pharmaceuticals (NASDAQ:TNXP) Coverage Initiated at initiated coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXPFree Report) in a report issued on Thursday. The firm issued a sell rating on the stock.

Separately, Dawson James started coverage on shares of Tonix Pharmaceuticals in a research report on Wednesday, February 28th. They issued a buy rating and a $96.00 price target for the company.

Read Our Latest Analysis on Tonix Pharmaceuticals

Tonix Pharmaceuticals Stock Performance

TNXP opened at $0.10 on Thursday. The company has a quick ratio of 0.87, a current ratio of 1.47 and a debt-to-equity ratio of 0.06. The firm has a market cap of $9.95 million, a PE ratio of -0.02 and a beta of 2.16. The business has a fifty day simple moving average of $5.41 and a 200-day simple moving average of $9.67. Tonix Pharmaceuticals has a fifty-two week low of $0.10 and a fifty-two week high of $1.99.

Tonix Pharmaceuticals (NASDAQ:TNXPGet Free Report) last released its quarterly earnings results on Monday, May 13th. The company reported ($5.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($16.64) by $10.88. The company had revenue of $2.48 million during the quarter, compared to analyst estimates of $4.00 million. As a group, equities analysts predict that Tonix Pharmaceuticals will post -2.58 EPS for the current fiscal year.

Hedge Funds Weigh In On Tonix Pharmaceuticals

Several hedge funds have recently bought and sold shares of TNXP. Armistice Capital LLC bought a new stake in shares of Tonix Pharmaceuticals during the 3rd quarter worth about $790,000. Sabby Management LLC acquired a new stake in Tonix Pharmaceuticals in the 3rd quarter worth approximately $680,000. Finally, Acadian Asset Management LLC boosted its position in Tonix Pharmaceuticals by 260.6% during the first quarter. Acadian Asset Management LLC now owns 335,373 shares of the company’s stock worth $61,000 after purchasing an additional 242,358 shares during the period. 82.26% of the stock is owned by institutional investors and hedge funds.

Tonix Pharmaceuticals Company Profile

(Get Free Report)

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

Read More

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with's FREE daily email newsletter.